A phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2527-2537

  Garrison, Mitchell A ^a   Hammond, Lisa A ^b   Geyer Jr , Charles E ^c   Schwartz, Garry ^a   Tolcher, Anthony W ^b   Smetzer, Leslie ^b   Figueroa, Jose A ^c   Ducharme, Murray ^d   Coyle, John ^e   Takimoto, Chris H ^b   De Jager, Robert L ^e   Rowinsky, Eric K ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b CTRC Institute for Drug Development   (United States)

^c Joe Arrington Cancer Center   (United States)

^d MDS Inc   (Canada)

^e Daiichi Pharmaceutical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; EXATECAN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CANCER; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTINUOUS INFUSION; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG SOLUBILITY; DRUG TOLERABILITY; FEMALE; HUMAN; IC 50; KIDNEY CANCER; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; NEUTROPENIA; PANCREAS CANCER; PAROTID GLAND CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; THYMOMA; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, CHEMICAL; NEOPLASMS; TIME FACTORS;

EID: 12444261674     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Slichenmyer, W. J. Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogs as anticancer agents. J. Natl. Cancer Inst. (Bethesda), 85: 272-291, 1993.
2. Bedeschi, A., Candiani, I., Geroni, C., and Capolongo, L. Water-soluble campothecin derivatives. Drugs of the Future, 22: 1259-1266, 1997.
3. Takimoto, C. H., Kieffer, L. V., and Arbuck, S. G. DNA topoisomerase I-inhibitors. Cancer Chemother. Bio. Resp. Mod., 17: 80-113, 1997.
4. Verschraegen, C. F., Royce, M. Hammond, L., and Rowinsky, E. K. Exatecan. Curr. Opin. Oncol. End. Met. Invest. Drugs, 2: 312-313, 2000.
5. Mitsui, I., Kumazawa, E., Hirota, Y., Aonuma, M., Sugimori, M., Ohsuki, S., Uoto, K., Ejima, A., Terasawa, H., and Sato, K. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn. J. Cancer Res., 86: 776-782, 1995.
6. Nomoto, T., Nishio, K., Ishidia, T., Mori, M., and Saijo, N. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f. Jpn. J. Cancer Res., 89: 1179-1186, 1998.
7. Takiguchi, S., Kumazawa, E., Shimazoe, T., Tohgo, A., and Kono, A. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Jpn. J. Cancer Res., 88: 760-769, 1997.
8. Joto, N., Ishii, M., Minami, M., Kuga, H., Mitsui, I., and Tohgo, A. DX8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int. J. Cancer, 72: 680-686, 1997.
9. Kumazawa, E., Jimbo, T., Ochi, Y., and Tohgo, A. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother. Pharmacol. 42: 210-220, 1998.
10. Hendricks, C. B., Rowinsky, E. K., Grochow, L. B., Donehower, R. C., and Kaufmann, S. H. Effect of P-glycoprotein expression on accumulation and cytotoxicity of topotecan (SK &F 104864), a new camptothecin analog. Cancer Res., 52: 2268-2278, 1992.
11. Chen, A. Y., Yu, C., Potmesil, M., Wall, M. E., Wani, M. C., and Liu, L. F. Camptothecin overcomes mdr1-mediated resistance in human KB carcinoma cells. Cancer Res., 51: 6039-6044, 1991.
12. Tsuruo, T., Matsuzaki, T., Matsushita, M., Saito, H., and Yokokura, T. Antitumor activity of CPT-11, a new derivative of camptothecin, against pleotropic drug resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol., 21: 71-74, 1988.
13. Mattern, M. R., Hofmann, G. A., Polsky, R. M., Funk, L. R., McCabe, F. L., and Johnson, R. K. In vitro and in vivo effects of clinically important camptothecin analogues in multi-drug resistant cells. Oncol. Res., 5: 467-474, 1993.
14. Yang, C. H., Schneider, E., Kuo, M. L., Volk, E. L., Rocchi, E., and Chen, Y. C. BCRP/MXP/ABCP expression in topotecan resistant human breast carcinoma cells. Biochem. Pharmacol., 60: 831-837, 2000.
15. Ishii, M., Iwana, M., Mitsui, I., Minami, M., and Imagawa, S. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on variant drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the the human lung cancer cell line PC-6. Anticancer Drugs, 11: 353-362, 2000.
16. Rowinsky, E. K., Johnson, T. R., Geyer, C. E., Hammond, L. A., Eckhardt, S. G., Drengler, R., Smetzer, L., Coyle, J., Rizzo, J., Schwartz, G., Tolcher, A., Von Hoff, D. D., and De Jager, R. L. DX-8951f (exatecan mesylate), a hexacyclic camptothecin analog on a daily x 5 schedule: a Phase I and pharmacokinetic study in advanced solid malignancies. J. Clin. Oncol., 18: 3151-3163, 2000.
17. Minami, H., Fujii, H., Igarashi, T., Itoh, K., Tamanoi, K., Oguma, T., and Sasaki, Y. Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks. Clin. Cancer Res., 7: 3056-3064, 2001.
18. Royce, M. E., Hoff, P. M., Dumas, P., Lassere, Y., Lee, J. J., Coyle, J., Ducharme, M. P., De Jager, R., and Pazdur, R. Phase I pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J. Clin. Oncol., 19: 1493-1500, 2001.
19. Vey, N., Giles, F. J., Kantarjian, H., Smith, T. L., Beran, M., and Jeha, S. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia. Clin. Cancer Res., 6: 731-736, 2000.
20. D'Adamo, D., Hammond, L., Donehower, R., Sharma, S., Aird, S., Kelsen, D., Ochoa, L., Rowinsky, E. K., De Jagger, R., and O'Reilly, E. M. Final results of a Phase II study of DX-8951f (exatecan mesylate) in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol., 20: 134a, 2001.
21. Patt, Y. Z., Rowinsky, E., O'Reilly, E., Eckardt, S. G., Duggal, A., Lubicz, P., Dumas, A., Lubicz, P., Dumas, P., Brown, T., and De Jagger, R. Phase II trial of DX-8951f (exatecan mesylate) in hepatocellular carcinoma; a final analysis. Proc. Am. Soc. Clin. Oncol., 21: 139a, 2002.
22. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., Vinci, R. Z., et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol., 12: 553-559, 1994.
23. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Blum, R. H., Zeleniuch-Jacquotte, A., et al. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a Phase I and pharmacodynamic study. Clin. Cancer Res., 3: 1245-1252, 1997.
24. Liebes, L., Potmesil, M., Kim, T., Pease, D., Buckley, M., Fry, D., Cho, J., Adler, H., Dar, K., Zeleniuch-Jacquotte, A., and Hochster, H. Pharamcodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin. Cancer Res., 4: 545-557, 1998.
25. Takimoto, C. H., Forero, F., Schwartz, G. H., Tolcher, A. W., Hammond, L., Patnaik, A., Ducharme, M., Cooke, B., De Jagger, R., and Rowinsky, E. K. A Phase I study of DE-310 administered as a 3-hour infusion every 4 weeks to patients with advanced solid tumors or lymphoma. Eur. J. Cancer, 38 (Suppl. 7): S46, 2002.
26. Goodman, S. N., Zahurak, M. L., and Piantadosi, S. Some practical improvements in the continual reassessment method in Phase I studies. Stat. Med., 14: 1149-1161, 1995.
27. Guidelines for the Reporting of Adverse Drug Reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1988.
28. Gibaldi, M., and Perrier, D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982.
29. Metzler, C. M. Extended least squares (ELS) for pharmacokinetic models. J. Pharmacol. Sci., 76: 565-571, 1987.
30. Lalonde, R. L. Pharmacodynamics. In: W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacoknetics: Principles of Therapeutic Drug Monitoring, pp. 4-1-4-33. Vancouver, WA: Applied Therapeutics, 1992.
31. D'Argenio, D. Z., and Schumitzky, A. ADAPT-II Users Manual. Los Angeles, CA: Biomedical Simulation Resource, University of Southern California, Los Angeles, 1997.
32. Yamaoka, K., Nakagawa, T., and Uno, T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6: 165-175, 1978.
33. Daiichi Pharmaceutical Corp. DX-8951f for Injection. Investigators Brochure, 2nd ed. Fort Lee, NJ: Daiichi Pharmaceutical Corp., 1998.
34. Tamayo, C., Richardson, M. A., Diamond, S., and Skoda, I. The chemistry and biological activity of herbs used in Flor-Essence herbal tonic and Essiac. Phytother. Res., 14: 1-14, 2000.
35. Kaegi, E. Unconventional therapies for cancer: 1. Essiac. Can. Med. Assoc. J., 158: 897-902, 1998.
36. Boik, J. Natural Compounds in Cancer Therapy. Princeton, MN: Oregon Medical Press, 2001.
37. Grochow, L. B., Rowinsky, E. K., Johnson, R., Ludeman, S., Kaufmann, S. H., McCabe, F. L., Smith, B. R., Hurowitz, L., DeLisa, A., Donehower, R. C., et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos., 20: 706-713, 1992.
38. Rivory, L. P., Bowles, M. R., Robert, J., and Pond, S. M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxyesterase. Biochem. Pharmacol., 52: 1103-1111, 1996.
39. Gupta, E., Wang, X., Ramirez, J., and Ratain, M. J. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother. Pharmacol., 39: 440-444, 1997.
40. Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T. L., Rock, M. K., and Donehower, R. C. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res., 54: 427-436, 1994.